Business
Who is winning global tech race? | The Express Tribune
The Global AI Summit kicks off at the Saudi capital Riyadh, September 13, 2022. PHOTO:Twitter Al Arabiya
KARACHI:
“China is going to win the AI race.” The remark sent ripples through Silicon Valley and beyond when Jensen Huang, CEO of US chipmaking giant Nvidia, made it at an AI summit in London earlier this month. Huang, whose company dominates the global AI chip market, later softened his position, saying China is merely “nanoseconds behind America.”
But Greg Slabaugh, Professor of Computer Vision and AI at Queen Mary University of London, is convinced that China has “already won” the AI race. And he made a startling revelation to back up his claim: of all the papers presented at the 2025 International Conference on Computer Vision in Hawaii, half were authored by Chinese researchers – far outstripping the US at 17%. Factor in Chinese nationals working abroad, and the gap would widen even further.
Three years before Huang’s candid acknowledgement, the Australian Strategic Policy Institute had reported that China leads in 57 out of 64 critical technologies – from quantum sensors and AI to robotics and semiconductors – while the US maintains an edge in far fewer areas, such as biotechnology and aerospace. This marks a dramatic reversal from 2003 to 2007, when the US led in 60 of 64 technologies and China in just three. Beijing’s current dominance stems from a high-impact research ecosystem in which, in some fields, it holds something close to a near-monopoly.
This meteoric rise, especially in AI, couldn’t be stymied by US efforts to limit China’s access to advanced chips and manufacturing equipment, which were intended to maintain America’s edge in the sector. Unlike past advantages based on cheap labour or scale, China’s AI lead is structural, built on concerted strategy, coordinated investment, and an energy ecosystem optimised for massive computational growth.
The AI revolution is, at its core, a revolution of power – in both senses of the word. Training the largest data models requires a huge computing capacity, which is powered by electricity on a colossal scale. By the decade’s end, experts say, AI data centres could consume more power than some mid-sized nations. And China holds a decisive edge in this high-voltage contest. Its subsidised electricity, flexible regulation, and capacity to execute large-scale projects at rapid speed have led to the mushrooming of AI infrastructure nationwide. From data-centre clusters in Inner Mongolia to renewable-powered server farms in Sichuan, Beijing has built an energy foundation capable of sustaining AI’s exponential growth. On the contrary, US tech giants are increasingly hamstrung by a growing web of constraints. The American electricity grid is old and fragmented, creating logistical and regulatory bottlenecks. Microsoft has conceded that energy shortages are slowing the expansion of its data centre. Chinese authorities, meanwhile, have turned energy planning into a national security priority – integrating AI, cloud computing, and grid modernisation into one strategic blueprint.
While Western firms like OpenAI and Anthropic pursue closed, commercial AI models, Chinese developers have doubled down on open-weight systems – models whose trained parameters are freely available. The result has been an open-source explosion that is transforming global software development. Chinese open-source AI downloads have now surpassed those from the US, according to venture capital firm a16z. Companies such as DeepSeek, MiniMax, Z.ai, and Moonshot are releasing high-performance models at a fraction of US prices.
China’s innovation often lies not in raw capability, but in accessibility and cost efficiency. Airbnb CEO Brian Chesky recently revealed that his company had replaced OpenAI’s ChatGPT with Alibaba’s Qwen model, calling it “fast and cheap.” Chamath Palihapitiya, CEO of Social Capital, said his firm has switched to Moonshot’s Kimi K2, describing it as “way more performant” than American rivals.
Conflicting approaches are at play here. The United States, by its own admission, wants to maintain global leadership in AI to secure its economic competitiveness. China, on the other hand, pushes for democratisation of AI, promoting open cooperation, capacity building for developing nations, and an “AI for the public good.” With this approach, Beijing has flipped one of Washington’s strategic levers. American export controls – meant to slow Chinese progress by denying access to cutting-edge chips – have instead spurred Chinese firms to build leaner models that run on older hardware. “They’ve actually encouraged Chinese companies to be more resourceful,” said AI researcher Toby Walsh. “It’s exactly what happened with solar panels – constraints made them smarter and cheaper.”
The story doesn’t end there. One of the most consequential areas of Chinese dominance is remote sensing: the science of gathering data from a distance through satellites, drones, and advanced sensors. A recent global analysis of 126,000 peer-reviewed papers found that China produced nearly 47% of all remote sensing research between 2021 and 2023. The American share, which stood at 88% during the Cold War, has fallen to just 9%. The patent landscape tells the same story. Among the top 19 global patent filers in remote sensing between 2021 and 2023, Chinese institutions accounted for 62%. Why does this matter? Because remote sensing underpins nearly every next-gen technology – from self-driving cars and smart cities to climate modeling and precision agriculture. Whoever controls the sensors, data flows, and analytic algorithms effectively controls the informational foundation of modern economies.
That said, China’s leap was no accident. Since the early 2000s, Beijing has strategically targeted the field for heavy investment under national programmes like the “973 Plan,” pairing state funding with private enterprise. The result: a vast ecosystem of universities, startups, and ministries working in concert. The US, by contrast, has relied heavily on NASA and the private sector. But fragmented research funding, bureaucratic inertia, and inconsistent industrial policy have eroded its early lead. When one country produces nearly half of global output in a strategic domain, and controls most patents and funding, it is shaping the next generation of value chains.
China’s stratospheric rise extends far beyond data and algorithms. In sector after sector, Western companies find themselves being out-produced, out-priced, and out-innovated. In automobiles, Chinese brands are redefining global competition. In 2024, Chinese carmakers captured 7.4% of all passenger car sales in Europe, nearly doubling their share within a year. EV maker Leapmotor posted a staggering 7,000% jump in sales, while BYD and Chery continue their European expansion with EVs far more affordable than Western models. This is why Ford CEO Jim Farley recently issued a blunt warning: “They have enough production capacity in China to serve the entire North American market.”
The same dynamic plays out in wind power, where Chinese manufacturers like Goldwind, Envision, and Mingyang now occupy the top four global slots – pushing Western rivals Siemens Energy, GE, and Vestas down the rankings. Chinese turbines are up to 50% cheaper, thanks to economies of scale and domestic demand that dwarfs anything in Europe or the US.
Having said that, all is not lost for the West, particularly the US, which still dominates the premium end of AI, biotechnology, and aerospace. Yet Washington must rethink its approach: instead of trying to slow China’s rise through export controls and strategic containment, it should focus on large-scale investment in energy infrastructure, R&D, and education. At the same time, it needs to face the new reality.
The writer is an independent journalist with special interest in geoeconomics
Business
Home heating oil costs in rural Lancashire doubles – councillors
One elderly couple had to find £1,000 for an oil delivery and suppliers are not giving quotes, a councillor says.
Source link
Business
Middle East conflict may hit India’s exports beyond region if prolonged, says government – The Times of India
A prolonged conflict in Middle East could begin to hurt India’s exports not just to the region but also to other global markets, as disrupted supply chains ripple outward, commerce secretary Rajesh Agrawal said on Saturday, He also urged the pharmaceutical industry to reduce dependence on imported raw materials and build more resilient export and import linkages.Speaking on the sidelines of ‘Chintan Shivir – Scaling Up Pharma Exports’ in Hyderabad, Agrawal said the government has already seen an impact on both imports and exports over the past month because of the Middle East crisis, with energy imports and regional trade flows under pressure.
“Middle East is also an important market. Around 12-13 per cent of our exports go to the region. So, that will directly get impacted. And if it goes on for long, maybe our exports to other parts of the world will also get impacted as some of the value chains will rotate back. We are cognizant of it,” Agrawal told reporters, as per news agency PTI.He said the exact impact of the conflict on India’s trade would become clearer in the next couple of weeks, but indicated that both exports and imports could see some decline.“And I assume, it will not only be a one-way traffic, in terms of export going down, but it will also be imports having some downfall,” he said.Agrawal cautioned that even if the war ends soon, the disruption may linger for months or even years, depending on the extent of damage to supply chains and infrastructure.“So, at this juncture, it will be very difficult to take a very long-term view on it,” he said.He said the Centre is trying to ensure that supply chains face the minimum possible disruption, while acknowledging that some trade numbers may soften in the near term.
Pharma sector already feeling supply pressure
The commerce secretary said the pharmaceutical sector has already seen some impact in the availability of key intermediates and solvents because supply chains are getting affected by the regional crisis.Agrawal said all arms of the government are working to prioritise limited LPG supply and are attempting to ease the situation by diversifying imports and sourcing from alternative suppliers.“So, as we are able to resolve that overall supply, we will try to alleviate some of the pain in every sector. The Pharma sector will be one of the priority sectors,” he said.He added that the government and industry are jointly working on ways to make supply chains more resilient.
Call for self-reliance in APIs, bulk drugs and intermediates
At the same event, Agrawal asked the pharmaceutical industry to use the current geopolitical uncertainty as a trigger to reduce dependence on critical imported inputs and strengthen domestic capacity.Addressing industry stakeholders in Hyderabad, he stressed “the importance of ensuring greater self-reliance by meeting 80-90 per cent (or higher) of domestic pharmaceutical requirements through indigenous production, while reducing critical import dependencies in APIs, bulk drugs, and intermediates”.He also emphasised the “importance of insulating import supply chains in a geopolitically fragmented world, where availability may be important”.Agrawal called for a broader strategic repositioning of India as a global hub for quality, affordable pharmaceuticals, saying that quality would remain the decisive factor in healthcare. He urged the sector to build a stronger quality ecosystem to enhance global trust and align with emerging areas such as biologics and biosimilars.He also encouraged the industry to shift from a volume-driven to a value-driven model, with greater focus on innovation and new patents, while maintaining India’s strength in generics.
Exports remain on positive path despite uncertainty
Despite the geopolitical overhang, Agrawal said India’s exports in the last financial year were expected to remain on a positive trajectory.The broader pharmaceutical export picture remains resilient. India’s pharma exports stood at $30.47 billion in 2024-25, up 9.4 per cent over the previous year.During April–February 2025-26, pharma exports reached $28.29 billion, registering growth of over 5 per cent compared with the corresponding period of the previous year.India remains the third-largest producer of pharmaceuticals globally by volume and 14th by value, underscoring both the sector’s scale and the stakes involved in insulating it from external shocks.
Business
India Pharmaceutical Exports: India’s pharma exports rise 5.6% to $28.29 billion till Feb in FY26; sector seen doubling to $130 billion by 2030 – The Times of India
India’s pharmaceutical exports remained on a growth track in the last financial year despite global headwinds, crossing $28 billion during April–February FY26, while industry leaders said the sector is on course to nearly double in size to $130 billion by 2030.Speaking at the inaugural session of the ‘Chintan Shivir: Scaling Up Pharma Exports’ on Saturday, K Raja Bhanu, director general of the Pharmaceuticals Export Promotion Council of India (Pharmexcil), said pharma exports stood at $28.29 billion in April–February FY26, marking a 5.6 per cent increase over the same period of FY25.“Despite global challenges, pharmaceutical exports have been among the few sectors to maintain growth momentum. Exports during April–February FY26 stood at $28.29 billion, reflecting a growth of 5.6 per cent compared to the same period in FY25, led by formulations, biologicals, vaccines and AYUSH products,” Bhanu said.Bhanu said the Indian pharmaceutical sector, currently valued at around $60 billion, is projected to grow to $130 billion by 2030. He added that pharma exports reached $30.47 billion in FY2024–25, recording a 9.4 per cent year-on-year growth despite global pricing pressures and trade volatility.He said Pharmexcil is targeting $65 billion in exports by 2030, backed by policy prioritisation, diversification beyond traditional markets, higher FDI inflows and faster regulatory clearances.India currently ranks third globally in pharmaceutical production by volume, with shipments reaching more than 200 markets, he said. Bhanu also noted that over 60 per cent of India’s pharma exports go to highly regulated markets, highlighting the sector’s quality and compliance standards.According to him, the United States accounts for 34 per cent of India’s pharmaceutical exports, followed by Europe at 19 per cent.Commerce secretary Rajesh Agrawal said the sector is likely to stay on a positive trajectory even if export targets prove difficult to meet in dollar terms, given the weakening rupee.“The target we have set appears difficult to meet, but we will remain on a positive trajectory,” Agrawal said.He added that regardless of whether targets are achieved in dollar terms, export growth would still reflect positively in rupee terms as the Indian currency continues to weaken against the US dollar.Pharmexcil chairman Namit Joshi said India is likely to end the current financial year at levels comparable to FY25, while flagging the effect of front-loaded US buying.“That is why we expect to end up close to last year’s performance, with some growth coming from that,” Joshi said.Joshi said tariff-related issues in 2025 led to higher procurement of medicines worth $1.6 billion in the US, above normal levels, and that this is expected to influence FY26 numbers.
US tariff backdrop may shape future outlook
While the immediate focus remains on export resilience, the external environment—especially in the US, India’s biggest pharma market—could become a key variable going forward.The US has announced a fresh tariff framework targeting patented drugs and certain high-value pharmaceutical ingredients manufactured outside America, with duties of up to 100 per cent set to take effect between August and September 2026 after a transition period.However, the near-term hit to India may be limited because generic medicines are currently exempt, and about 90 per cent of India’s pharmaceutical exports to the US are generics, as per a GTRI report. The report said India exported $9.7 billion worth of pharmaceuticals to the US in 2025, accounting for 38 per cent of its global pharma exports of $25.8 billion.
-
Sports1 week agoIllinois defense gets tough, ousts Houston to reach Elite Eight
-
Sports1 week agoUSMNT handed reality check by Doku, Belgium ahead of World Cup
-
Entertainment1 week agoLee Sang-bo dies at 45: Funeral details revealed
-
Sports1 week ago2026 NCAA men’s hockey tournament: Schedule, results
-
Fashion1 week agoChina rolls out tariff cuts on Congo imports from April 1
-
Fashion1 week agoEU apparel imports slump 15.48% YoY in Jan; Bangladesh hardest hit
-
Uncategorized6 days ago
[CinePlex360] Please moderate: “Further tariff
-
Tech1 week agoSkip the TSA Line: Where to Find Travel by Bus, Train, and Boat
